Literature DB >> 14634267

Beneficial effect of steroid pulse therapy on acute viral encephalitis.

Ayako Nakano1, Ryuichi Yamasaki, Shuichi Miyazaki, Nobuaki Horiuchi, Makoto Kunishige, Takao Mitsui.   

Abstract

Corticosteroids are often used in the treatment of acute viral encephalitis, although the efficacy of corticosteroid therapy has not been proven. We examined the effects of high-dose corticosteroid therapy on acute viral encephalitis in 5 patients with progressive disturbances of consciousness. In 3 patients who were treated within 5 days after the onset of illness, pulse therapy dramatically reduced the degree of consciousness disturbance. They became alert within 24 h, and then neurological symptoms gradually improved. Corticosteroid therapy in the other 2 patients, in whom treatment was started more than 3 weeks after the onset of illness, was not as effective, but repeated therapy at 2-week intervals resulted in complete recovery. These findings suggest that high-dose corticosteroid therapy is effective, particularly for disturbances of consciousness, an important prognostic factor in acute viral encephalitis. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634267     DOI: 10.1159/000073864

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  10 in total

1.  Japanese encephalitis (JE). Part I: clinical profile of 1,282 adult acute cases of four epidemics.

Authors:  N B S Sarkari; A K Thacker; S P Barthwal; V K Mishra; Shiv Prapann; Deepak Srivastava; M Sarkari
Journal:  J Neurol       Date:  2011-06-17       Impact factor: 4.849

Review 2.  Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Clin Microbiol Rev       Date:  2020-02-12       Impact factor: 26.132

3.  Clinical use of steroids in viral central nervous system (CNS) infections: three challenging cases.

Authors:  Adam Kroopnick; Dan Tong Jia; Kathryn Rimmer; Vivian S Namale; Carla Kim; Ugoada Ofoezie; Kiran T Thakur
Journal:  J Neurovirol       Date:  2021-10-01       Impact factor: 2.643

Review 4.  Herpes simplex type I (HSV-1) infection of the nervous system: is an immune response a good thing?

Authors:  Christopher D Conrady; Douglas A Drevets; Daniel J J Carr
Journal:  J Neuroimmunol       Date:  2009-10-09       Impact factor: 3.478

5.  Epstein-Barr virus encephalitis with substantia nigra involvement.

Authors:  Tamer Çelik; Ümit Çelik; Orkun Tolunay; Mustafa Kömür; Hüseyin Başpınar; Cengiz Yılmaz; Gülen Mert; Dinçer Yıldızdaş
Journal:  J Pediatr Neurosci       Date:  2015 Oct-Dec

Review 6.  Infectious encephalitis: Management without etiological diagnosis 48hours after onset.

Authors:  P Fillatre; Y Crabol; P Morand; L Piroth; J Honnorat; J P Stahl; M Lecuit
Journal:  Med Mal Infect       Date:  2017-03-15       Impact factor: 2.152

7.  Ataxia and Encephalitis in a Young Adult with EBV Mononucleosis: A Case Report.

Authors:  Rashid S Hussain; Naaz A Hussain
Journal:  Case Rep Neurol Med       Date:  2013-05-28

8.  Clinical Study on the Melarsoprol-Related Encephalopathic Syndrome: Risk Factors and HLA Association.

Authors:  Jorge Seixas; Jorge Atouguia; Teófilo Josenando; Gedeão Vatunga; Constantin Miaka Mia Bilenge; Pascal Lutumba; Christian Burri
Journal:  Trop Med Infect Dis       Date:  2020-01-01

Review 9.  Efficacy and safety of intravenous immunoglobulins for the treatment of viral encephalitis: a systematic literature review.

Authors:  Judith N Wagner; Annette Leibetseder; Anna Troescher; Juergen Panholzer; Tim J von Oertzen
Journal:  J Neurol       Date:  2021-03-06       Impact factor: 6.682

10.  Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis.

Authors:  Thomas Whitfield; Cristina Fernandez; Kelly Davies; Sylviane Defres; Michael Griffiths; Cory Hooper; Rebecca Tangney; Girvan Burnside; Anna Rosala-Hallas; Perry Moore; Kumar Das; Mark Zuckerman; Laura Parkes; Simon Keller; Neil Roberts; Ava Easton; Saber Touati; Rachel Kneen; J P Stahl; Tom Solomon
Journal:  BMJ Open       Date:  2021-07-22       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.